Ranbaxy gets USFDA nod to market Loperamide Hydrochloride
Mumbai, Sept 11 (UNI) Ranbaxy Laboratories today received approval from the US Food and Drug Administration to manufacture and market tablets used to control symptoms of diarrhea plus bloating, pressure, and cramps commonly referred to as gas.
Announcing this to the Bombay Stock Exchange, the company informed that the tablets, known as Loperamide Hydrochloride and Simethicone Tablets (OTC), in medical terminology, had achieved total sales of USD 25.3 million, in the OTC market.
''Ohm will again be a leading participant in the launch of another successful and proven Loperamide formulation.'' senior director (OTC sales and marketing) of Ohm Laboratories, Robert Haywood said.
Ohm Laboratories, based in North Brunswick, New Jersey, USA, is a wholly owned subsidiary of Ranbaxy. Ohm is engaged in the sale and distribution of generic and branded OTC products in the US.
UNI SN WD VKG1605